ArchiveJuly 2012

Stress management on trial as a DMT

Epub: Mohr et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul. OBJECTIVES: This trial examined the efficacy of a stress management program in reducing neuroimaging markers of MS disease activity. METHODS: A total of 121 MSers with relapsing forms of MS were randomized to receive stress management therapy for MS (SMT-MS) or a wait-list...

Research: surgery for facial pain

Mohammadi et al. Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis. Neurosurgery. 2012;71(2):E563-4. INTRODUCTION: Trigeminal neuralgia (TN) is relatively frequent in Multiple Sclerosis (MS) patients and procedural treatments are less effective than when used for classical TN. Outcomes from direct comparisons between different procedures for MS-related TN is lacking...

FDA warns about seizures with MS drug Ampyra or Fampridine

The U.S. Food and Drug Administration (FDA) on Monday said MSers who take the drug Ampyra (known as Fampridine in Europe), have a higher risk of seizures when starting the treatment. The FDA also updated the label for Ampyra / Fampridine , which is approved to help MSers walk, to warn about the need to check kidney function before people start taking it, and every year after that. Source...

Research: predicting MS

Epub: Villar et al. High Levels Of Cerebrospinal Fluid Free Kappa Chains Predict Conversion To Multiple Sclerosis.Clin Chim Acta. 2012 Jul BACKGROUND: A clinically isolated syndrome (CIS) may be the initial presentation of multiple sclerosis (MS). However, some CIS never develop MS. The identification of patients at risk of MS conversion is crucial as early treatment may improve their outcome...

Rebound in MS disease activity on fingolimod withdrawal

Epub: Hakiki et al. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler. 2012 Jul. The objective of this study is to report the limited experience on fingolimod suspension in MSers. The clinical and MRI outcomes are presented in 6 MSers after fingolimod discontinuation. Within three months from fingolimod suspension, 5 MSers returned to...

Research: vitamin D and the main MS genetic risk factor

Epub: Nolan et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk.  Neurology. 2012 Jul 11. “This research is what I call hard-core functional genomics and supports other studies already published. All genes have an area upstream of the protein coding reading that controls whether they are switched ON or OFF. The area that controls on the ON...

Research: Another action for Gilenya

Epub: van Doorn et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012 Jul. Alterations in sphingolipid metabolism are described to contribute to various neurological disorders. We here determined the expression of enzymes involved in the sphingomyelin cycle and their products in postmortem...

Grand Challenges in MS (3): changing sex ratio

Why is the incidence of MS increasing amongst woman? To prove that MS is caused by a single factor or the interaction of several factors it has to explain everything we know about the epidemiology of the disease. Epidemiology = the branch of medicine involved with the study of disease in the population; epidemiology deals with the study of the causes, distribution, and control of disease in...

Research: the MS diagnosis just got better in the Netherlands

Epub: Kramer et al. Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996-2008. Neuroepidemiology. 2012 Jul 17;39(2):96-102. Background : These investigators estimated the MS incidence (number of cases per year) in the Netherlands in relation to vaccine safety. Methods: A retrospective cohort study (1996-2008) was conducted using a population-based general practice...

Translate

Categories

Recent Posts

Recent Comments

Archives